Vaxcyte, Inc. (PCVX)
After hours:
| Previous close | 111.60 |
| Open | 111.60 |
| Bid | 114.34 x 100 |
| Ask | 114.41 x 100 |
| Day's range | 111.16 - 114.61 |
| 52-week range | 45.00 - 121.06 |
| Volume | |
| Avg. volume | 958,828 |
| Market cap | 14.163B |
| Beta (5Y monthly) | 0.99 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -4.69 |
| Earnings date | 04 Nov 2024 - 08 Nov 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 149.29 |
Insider MonkeyVaxcyte, Inc. (PCVX): Among Hedge Funds’ Top Biotech Stock Picks
We recently compiled a list of the 10 Largest Biotech Hedge Funds and Their Top Stock Picks. In this article, we are going to take a look at where Vaxcyte, Inc. (NASDAQ:PCVX) stands against the other biotech stocks. The ability to successfully make money through investment requires deep thinking and analysis. Even then, it’s not a […]
GlobeNewswireVaxcyte to Present at the 2024 Cantor Global Healthcare Conference
SAN CARLOS, Calif., Sept. 11, 2024 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, announced today that Company management will participate in a fireside chat at the 2024 Cantor Global Healthcare Conference on Wednesday, September 18, at 10:20 a.m. ET / 7:20 a.m. PT. A live webcast of the fireside chat can be accessed through the Investors & Media sec
- GlobeNewswire
Vaxcyte Announces Closing of $1.5 Billion Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
SAN CARLOS, Calif., Sept. 06, 2024 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, announced today the closing of its previously announced underwritten public offering of 12,087,378 shares of common stock at a public offering price of $103.00 per share and pre-funded warrants to purchase 2,427,184 shares of common stock at a public offering price of $
